Hepatitis C, insulin resistance and diabetes: Clinical and pathogenic data

Liver International

Volumn 29, Issue SUPPL. 2, 2009, Pages 13-25

  Serfaty, Lawrence ^a,b   Capeau, Jacqueline ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c HÔPITAL TENON   (France)

^d INSERM   (France)

Author keywords

Adiponectin; Diabetes; Hepatitis C virus; Insulin resistance; Steatosis; Tumour necrosis factor

Indexed keywords

ADIPONECTIN; C PEPTIDE; FATTY ACID; GAMMA INTERFERON; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ADIPONECTIN BLOOD LEVEL; ADIPOSE TISSUE; BODY MASS; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GENOTYPE; HEPATITIS C; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MACROPHAGE; METABOLIC DISORDER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STEATOSIS; VIRUS LOAD;

ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 1; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HEPACIVIRUS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; REACTIVE OXYGEN SPECIES;

EID: 59449099132     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01952.x     Document Type: Review

References (78)

1. McHutchison JG, Bacon BR. Chronic hepatitis C: An age wave of disease burden. Am J Manag Care 2005; 11: S286-95.
2. Di Bisceglie AM. Natural history of hepatitis C: Its impact on clinical management. Hepatology 2000; 31: 1014-8.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
4. Fraser GM, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996; 32: 526-30.
5. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
6. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-9.
7. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
8. Knobler H, Zhornicky T, Sandler A, et al. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003; 98: 2751-6.
9. Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab 2005; 90: 2240-3.
10. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
11. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006; 55: 123-30.
12. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7.
13. Grundy SM, Cleeman JI National Heart, Lung, and Blood Institute et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
14. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22.
15. Alberti KG, Zimmet P, Shaw J IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-62.
16. Radkowski M, Bednarska A, Horban A, et al. Infection of primary human macrophages with hepatitis C virus in vitro: Induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol 2004; 85: 47-59.
17. Dolganiuc A, Norkina O, Kodys K, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in cHCV infection. Gastroenterology 2007; 133: 1627-36.
18. Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-9.
19. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-65.
20. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000; 46: 260-9.
21. http://medicTnenet.com: http://www.medicinenet.com/insulin_resistance/ article.htm. Accessed July 2, 2008.
22. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-5.
23. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
24. Delgado-Borrego A, Liu Y-S, Jordan SH, et al. Prospective study of liver transplant recipients with HCV infection: Evidence for acausal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193-201.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
26. Stern SE, Williams K, Ferrannini E, et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005; 54: 333-9. Medscape article available at http://www.medscape.com/ viewarticle/498615.
27. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-9.
28. Grimbert S, Valensi P, Levy-Marchal C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996; 20: 544-8.
29. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
30. Okan V, Araz M, Aktaran S, et al. Increased frequency of HCV but not HBV infection in type 2 diabetic patients in Turkey. Int J Clin Pract 2002; 56: 175-7.
31. Sangiorgio L, Attardo T, Gangemi R, et al. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract 2000; 48: 147-51.
32. SimóR, Hernández C, GenescàJ, JardíR, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000.
33. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-6.
34. Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
35. Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study. Hepatology 2007; 46: 380-7.
36. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723-31.
37. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008; 28: 271-7.
38. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6.
39. Sánchez-Tapias JM, Diago M TeraViC-4 Study Group et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
40. Capeau J. Insulin signaling; mechanisms altered in insulin resistance. Med Sci (Paris) 2005; 21(Spec No): 34-9.
41. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 2005; 115: 718-27.
42. Taniguchi CM, Kondo T, Sajan M, et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 2006a; 3: 343-53.
43. Taniguchi CM, Tran TT, Kondo T, et al. Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci USA 2006; 103: 12093-7.
44. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004; 101: 10422-7.
45. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 2005; 33: 185-92.
46. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
47. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005; 54(Suppl. 2): S73-8.
48. Draznin B. Molecular mechanisms of insulin resistance: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: The two sides of a coin. Diabetes 2006; 55: 2392-7.
49. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394-8.
50. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6 dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-6.
51. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
52. Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005; 54: 3458-65.
53. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119(Suppl. 1): S10-6.
54. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-90.
55. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-8.
56. Kim JK. Fat uses a TOLL-road to connect inflammation and diabetes. Cell Metab 2006; 4: 417-9.
57. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-25.
58. Westerbacka J, Lammi K, Häkkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90: 2804-9.
59. Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007; 56: 2759-65.
60. Baranova A, Schlauch K, Elariny H, et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 2007; 17: 1111-8.
61. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56: 1960-8.
62. Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-61.
63. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-72.
64. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-8.
65. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
66. Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/ tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006; 24: 1349-57.
67. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-6.
68. Lecube A, Hernández C, GenescàJ, SimóR. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096-101.
69. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
70. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/ PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-92.
71. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
72. Barton LF, Runnels HA, Schell TD, et al. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol 2004; 172: 3948-54.
73. Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J Virol 2007; 81: 1727-35.
74. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
75. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.
76. Pazienza V, Clément S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
77. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: Genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008.
78. Cholet F, Nousbaum JB, Richecoeur M, et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004; 28: 272-8.